Sickle Cell Disease in Brazil: Current Management

Area of Science:

• Hematology
• Genetics
• Pharmacology

Background:

• Sickle cell disease (SCD) is an inherited red blood cell disorder caused by a specific mutation in the β-globin gene.
• It leads to abnormal hemoglobin S polymerization under deoxygenated conditions, resulting in red blood cell sickling, hemolysis, and vaso-occlusion.
• Vaso-occlusive crisis (VOC) is a primary complication, but SCD can lead to other severe health issues.

Purpose of the Study:

• To review recent data on sickle cell disease management and treatment options.
• To focus on available therapies, particularly in the context of Brazil.
• To highlight emerging treatments for SCD patients.

Main Methods:

• Literature review of recent data on sickle cell disease.
• Analysis of treatment options and their regional availability.
• Focus on specific new therapies and their approval status.

Main Results:

• Sickle cell disease is a growing global health concern, with increased incidence in the Americas and Africa.
• Disease management strategies differ significantly based on regional resources and socioeconomic factors.
• Crizanlizumab is an approved treatment option in Brazil, indicating advancements in SCD therapy.

Conclusions:

• There is a need for updated data on sickle cell disease treatments globally.
• Advancements in therapeutic options, such as crizanlizumab, are crucial for improving patient outcomes.
• Ensuring equitable access to new treatments for all SCD patients is a key challenge.